<?xml version="1.0" encoding="UTF-8"?><measure><measureDetails><uuid>40280381-3d61-56a7-013e-6abd73e15076</uuid><title>Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer</title><shortTitle>Onc_Breast_Cancer</shortTitle><emeasureid>140</emeasureid><guid>ac639794-cb3f-4f4f-8fa6-680300d5ed4e</guid><version>2</version><status>Complete</status><nqfid extension="0387" root="2.16.840.1.113883.3.560.1"/><period uuid="4b3f3581-55c5-43c0-8bc3-d40b856ab5ab"><startDate uuid="120e344b-f155-42fa-a5e0-aa3737d297e4">00000101</startDate><stopDate uuid="d717f2ba-3e16-41d4-b184-01b9af9c6cb1">00001231</stopDate></period><steward id="2.16.840.1.113883.3.526">American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)</steward><developers><developer id="2.16.840.1.113883.3.526">American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)</developer></developers><endorsement id="2.16.840.1.113883.3.560">National Quality Forum</endorsement><description>Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period</description><copyright>Copyright 2012 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved.</copyright><disclaimer>Physician Performance Measures (Measures) and related data specifications have been developed by the American Medical Association (AMA) - convened Physician Consortium for Performance Improvement(R) (PCPI[R]), American Society of Clinical Oncology, and National Comprehensive Cancer Network. These Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA, (on behalf of the PCPI). Neither the AMA, PCPI nor its members shall be responsible for any use of the Measures. 

THE MEASURES AND SPECIFICATIONS ARE PROVIDED ?AS IS? WITHOUT WARRANTY OF ANY KIND. 

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, American Society of Clinical Oncology, National Comprehensive Cancer Network, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT[R]) or other coding contained in the specifications. 

CPT(R) contained in the Measure specifications is copyright 2004-2012 American Medical Association. LOINC(R) copyright 2004-2012 Regenstrief Institute, Inc. 

This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2012 International Health Terminology Standards Development Organisation. ICD-10 copyright 2012 World Health Organization. All Rights Reserved.

Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].</disclaimer><scoring id="PROPOR">Proportion</scoring><types><type id="PROCESS">Process</type></types><stratification>None</stratification><riskAdjustment>None</riskAdjustment><aggregation>None</aggregation><rationale>Despite evidence suggesting the role of adjuvant endocrine therapy in lowering the risk of tumor recurrence, many female patients who should be receiving this therapy are not. 

This measure assesses whether patients with a certain stage of breast cancer (IC through IIIC) and ER/PR+ are currently receiving the therapy. 

There are allowable medical, patient, and system reasons to document instances in which a woman with stage IC through IIIC, ER/PR+ may not be a candidate for the therapy.</rationale><recommendations>Adjuvant therapy for postmenopausal women with hormone receptor?positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence. Aromatase inhibitors are appropriate as initial treatment for women with contraindications to tamoxifen. For all other postmenopausal women, treatment options include 5 years of aromatase inhibitors treatment or sequential therapy consisting of tamoxifen (for either 2 to 3 years or 5 years) followed by aromatase inhibitors for 2 to 3, or 5 years. (ASCO guidelines include narrative rankings) (ASCO, 2009) 

Patients intolerant of aromatase inhibitors should receive tamoxifen. Women with hormone receptor?negative tumors should not receive adjuvant endocrine therapy. (ASCO guidelines include narrative rankings) (ASCO, 2009) 

Patients with invasive breast cancers that are estrogen or progesterone receptor positive should be considered for adjuvant endocrine therapy regardless of patient age, lymph node status, or whether or not adjuvant chemotherapy is to be administered. (Category 2A) (NCCN, 2011).

The most firmly established adjuvant endocrine therapy is tamoxifen for both premenopausal and postmenopausal women. Prospective, randomized trials demonstrate that the optimal duration of tamoxifen appears to be five years. In patients receiving both tamoxifen and chemotherapy, chemotherapy should be given first, followed by sequential tamoxifen. A number of studies have evaluated aromatase inhibitors in the treatment of postmenopausal women with early-stage breast cancer. (Category 2A) (NCCN, 2011)

Patients with lymph node involvement or with tumors greater than 1 cm in diameter are appropriate candidates for adjuvant systemic therapy. (Category 1) For those with lymph node-negative, hormone receptor-positive breast cancer tumors greater than 1 cm, endocrine therapy with chemotherapy is recommended. (Category 1) (NCCN, 2011)</recommendations><improvementNotations>Higher score indicates better quality</improvementNotations><references><reference>Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer. J Clin Oncol: JCO. 2009;26:3756. Available at: http://www.asco.org. </reference><reference>National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2, 2011. Available at: http://www.nccn.org</reference></references><definitions>None</definitions><guidance>The denominator for this measure has been limited to patients with a first recorded breast cancer diagnosis within the past 5 years. The numerator captures patients who are prescribed adjuvant tamoxifen or AI, or received adjuvant tamoxifen or AI during the 12 month period. Date of breast cancer diagnosis is defined as date of pathologic diagnosis.</guidance><transmissionFormat>TBD</transmissionFormat><initialPatientPopDescription>All female patients aged 18 years and older with a diagnosis of breast cancer</initialPatientPopDescription><denominatorDescription>Equals Initial Patient Population with stage IC through IIIC, estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer</denominatorDescription><denominatorExclusionsDescription>None</denominatorExclusionsDescription><numeratorDescription>Patients who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period</numeratorDescription><numeratorExclusionsDescription>Not Applicable</numeratorExclusionsDescription><denominatorExceptionsDescription>- Documentation of medical reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient?s disease has progressed to metastatic, patient is receiving a gonadotropin-releasing hormone analogue, patient has received oophorectomy, patient is receiving radiation or chemotherapy, patient?s diagnosis date was &gt;= 5 years from reporting date, other medical reason)
- Documentation of patient reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient refusal, other patient reasons)
- Documentation of system reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient is currently enrolled in a clinical trial, other system reasons)</denominatorExceptionsDescription><measurePopulationDescription>Not Applicable</measurePopulationDescription><measureObservationsDescription>Not Applicable</measureObservationsDescription><supplementalData>For every patient evaluated by this measure also identify payer, race, ethnicity and sex.</supplementalData><qualityMeasureSet uuid="196b9463-8b12-4aeb-9a98-6f8485e27620">None</qualityMeasureSet>
<finalizedDate value="201404162149-0500"/>
</measureDetails><supplementalDataElements><elementRef id="40280381-3d61-56a7-013e-6abd73f95079" name="ONC Administrative Sex"/><elementRef id="40280381-3d61-56a7-013e-6abd73f9507a" name="Race"/><elementRef id="40280381-3d61-56a7-013e-6abd73f9507b" name="Ethnicity"/><elementRef id="40280381-3d61-56a7-013e-6abd73f9507c" name="Payer"/></supplementalDataElements><measureGrouping><group sequence="1"><clause displayName="Initial Patient Population 1" type="initialPatientPopulation" uuid="5C2B4885-A105-4CAE-9356-E6DD7BACF304"><logicalOp displayName="AND" type="and"><relationalOp displayName="&gt;= 18 years Starts Before Start Of" operatorType="Greater Than or Equal To" quantity="18" type="SBS" unit="years"><elementRef displayName="birth date : Patient Characteristic Birthdate" id="40280381-3d61-56a7-013e-6abd73f9507d" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp><functionalOp displayName="FIRST" type="FIRST" uuid="d27e5ae6-5659-4231-b1de-593be973307c"><relationalOp displayName="&lt;= 5 years Starts Before Or During" operatorType="Less Than or Equal To" quantity="5" type="SBOD" unit="years"><elementRef displayName="Occurrence A of Breast Cancer : Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73f9507f" type="qdm"/><relationalOp displayName="During" type="DURING"><logicalOp displayName="OR" type="or"><elementRef displayName="Occurrence A of Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95080" type="qdm"/><elementRef displayName="Occurrence A of Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp></relationalOp></functionalOp><functionalOp displayName="COUNT &gt;= 2  " operatorType="Greater Than or Equal To" quantity="2" type="COUNT" unit=" " uuid="6d8f9a40-c6ac-4e07-a80e-5e91a587528e"><relationalOp displayName="During" type="DURING"><logicalOp displayName="OR" type="or"><elementRef displayName="Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95081" type="qdm"/><elementRef displayName="Patient Provider Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95083" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp></functionalOp><elementRef displayName="Female : Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6abd73f95084" type="qdm"/></logicalOp></clause><clause displayName="Denominator 1" type="denominator" uuid="B06F5631-6E3C-4879-8BCF-95C6F07097E2"><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5087"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5088"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5089"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508a"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508b"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508c"/></elementRef></logicalOp><logicalOp displayName="OR" type="or"><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508d"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508e"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508f"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5090"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5091"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5098"/></elementRef></logicalOp></logicalOp><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5097"/></elementRef><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5093"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5094"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5095"/></elementRef></logicalOp><logicalOp displayName="OR" type="or"><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5096"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508d"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5098"/></elementRef></logicalOp></logicalOp><logicalOp displayName="AND" type="and"><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa508b"/></elementRef><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5096"/></elementRef></logicalOp></logicalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="Starts Before Or During" type="SBOD"><elementRef displayName="Occurrence A of Breast Cancer ER or PR Positive : Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73f95077" type="qdm"/><logicalOp displayName="OR" type="or"><elementRef displayName="Occurrence A of Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95080" type="qdm"/><elementRef displayName="Occurrence A of Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" type="qdm"/></logicalOp></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="3b237a03-1e56-4d85-9c46-cfef4f27b125"><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Occurrence A of Breast Cancer ER or PR Positive : Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73f95077" type="qdm"/><elementRef displayName="Occurrence A of Breast Cancer : Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73f9507f" type="qdm"/></relationalOp></functionalOp></logicalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="Starts Before Or During" type="SBOD"><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"><attribute mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6abd73fa5092"/></elementRef><logicalOp displayName="OR" type="or"><elementRef displayName="Occurrence A of Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95080" type="qdm"/><elementRef displayName="Occurrence A of Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" type="qdm"/></logicalOp></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="264de459-df97-4eab-a269-77ca0582c078"><relationalOp displayName="Starts Before Start Of" type="SBS"><elementRef displayName="Occurrence A of Clinical Staging Procedure : Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" type="qdm"/><elementRef displayName="Occurrence A of Breast Cancer : Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73f9507f" type="qdm"/></relationalOp></functionalOp></logicalOp></logicalOp></clause><clause displayName="Denominator Exceptions 1" type="denominatorExceptions" uuid="00589A88-3B6F-4635-9413-6EC2D913AD90"><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><relationalOp displayName="During" type="DURING"><logicalOp displayName="OR" type="or"><elementRef displayName="Radiation Therapy II : Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50aa" type="qdm"/><elementRef displayName="Chemotherapy : Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a5" type="qdm"/></logicalOp><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" type="qdm"/></relationalOp><relationalOp displayName="Starts Before Or During" type="SBOD"><logicalOp displayName="OR" type="or"><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy : Medication, Order" id="40280381-3d61-56a7-013e-6abd73fa5099" type="qdm"><attribute mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6abd73fb50a6"/></elementRef><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy : Medication, Order" id="40280381-3d61-56a7-013e-6abd73fa5099" type="qdm"><attribute mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6abd73fb50a7"/></elementRef><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy : Medication, Order" id="40280381-3d61-56a7-013e-6abd73fa5099" type="qdm"><attribute mode="Value Set" name="negation rationale" qdmUUID="40280381-3d61-56a7-013e-6abd73fb50a8"/></elementRef><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy Allergen : Medication, Allergy" id="40280381-3d61-56a7-013e-6aeaa35851dc" type="qdm"/><elementRef displayName="Allergy to Tamoxifen or Aromatase Inhibitor Therapy : Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73fa509f" type="qdm"/><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy : Medication, Intolerance" id="40280381-3d61-56a7-013e-6abd73fa509d" type="qdm"/><elementRef displayName="Intolerance to Tamoxifen or Aromatase Inhibitor Therapy : Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73fa509e" type="qdm"/><elementRef displayName="Gonadotropin-releasing hormone analogue medication : Medication, Active" id="40280381-3d61-56a7-013e-6abd73fa50a0" type="qdm"/><elementRef displayName="Bilateral Oophorectomy : Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a1" type="qdm"/><elementRef displayName="Metastatic Sites Common to Breast Cancer : Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73fb50a2" type="qdm"/><elementRef displayName="Clinical Trial Participant : Patient Characteristic Clinical Trial Participant" id="40280381-3d61-56a7-013e-6abd73fb50a3" type="qdm"/></logicalOp><logicalOp displayName="OR" type="or"><elementRef displayName="Occurrence A of Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95080" type="qdm"/><elementRef displayName="Occurrence A of Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" type="qdm"/></logicalOp></relationalOp></logicalOp></logicalOp></clause><clause displayName="Numerator 1" type="numerator" uuid="2F6B6343-7C3B-43F0-8345-F93E4614CFD7"><logicalOp displayName="AND" type="and"><logicalOp displayName="OR" type="or"><relationalOp displayName="During" type="DURING"><elementRef displayName="Tamoxifen or Aromatase Inhibitor Therapy : Medication, Order" id="40280381-3d61-56a7-013e-6abd73fa5099" type="qdm"/><logicalOp displayName="OR" type="or"><elementRef displayName="Occurrence A of Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95080" type="qdm"/><elementRef displayName="Occurrence A of Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" type="qdm"/></logicalOp></relationalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="Starts Before Or During" type="SBOD"><elementRef displayName="Occurrence A of Tamoxifen or Aromatase Inhibitor Therapy : Medication, Active" id="40280381-3d61-56a7-013e-6abd73fa509a" type="qdm"/><elementRef displayName="Occurrence A of Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95080" type="qdm"/></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="b65943b4-3741-4cd7-ba64-bcde630ef7d6"><relationalOp displayName="Ends Before Start Of" type="EBS"><elementRef displayName="Occurrence A of Tamoxifen or Aromatase Inhibitor Therapy : Medication, Active" id="40280381-3d61-56a7-013e-6abd73fa509a" type="qdm"/><elementRef displayName="Occurrence A of Office Visit : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95080" type="qdm"/></relationalOp></functionalOp></logicalOp><logicalOp displayName="AND" type="and"><relationalOp displayName="Starts Before Or During" type="SBOD"><elementRef displayName="Occurrence A of Tamoxifen or Aromatase Inhibitor Therapy : Medication, Active" id="40280381-3d61-56a7-013e-6abd73fa509a" type="qdm"/><elementRef displayName="Occurrence A of Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" type="qdm"/></relationalOp><functionalOp displayName="NOT" type="NOT" uuid="97e0dc05-ca7a-4ccc-9a08-07d9e0209ee2"><relationalOp displayName="Ends Before Start Of" type="EBS"><elementRef displayName="Occurrence A of Tamoxifen or Aromatase Inhibitor Therapy : Medication, Active" id="40280381-3d61-56a7-013e-6abd73fa509a" type="qdm"/><elementRef displayName="Occurrence A of Face-to-Face Interaction : Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" type="qdm"/></relationalOp></functionalOp></logicalOp></logicalOp></logicalOp></clause></group></measureGrouping><elementLookUp><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73f95077" instance="Occurrence A" name="Breast Cancer ER or PR Positive" oid="2.16.840.1.113883.3.526.3.1303" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73f95077" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Result" id="40280381-3d61-56a7-013e-6abd73f95078" instance="Occurrence A" name="Clinical Staging Procedure" oid="2.16.840.1.113883.3.526.3.1098" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73f95078" version="1"/><qdm codeSystemName="National Library of Medicine" datatype="Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6abd73f95079" name="ONC Administrative Sex" oid="2.16.840.1.113762.1.4.1" suppDataElement="true" taxonomy="Administrative Sex" uuid="40280381-3d61-56a7-013e-6abd73f95079" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Race" id="40280381-3d61-56a7-013e-6abd73f9507a" name="Race" oid="2.16.840.1.114222.4.11.836" suppDataElement="true" taxonomy="CDC" uuid="40280381-3d61-56a7-013e-6abd73f9507a" version="1"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Ethnicity" id="40280381-3d61-56a7-013e-6abd73f9507b" name="Ethnicity" oid="2.16.840.1.114222.4.11.837" suppDataElement="true" taxonomy="CDC" uuid="40280381-3d61-56a7-013e-6abd73f9507b" version="1"/><qdm codeSystemName="PHDSC" datatype="Patient Characteristic Payer" id="40280381-3d61-56a7-013e-6abd73f9507c" name="Payer" oid="2.16.840.1.114222.4.11.3591" suppDataElement="true" taxonomy="Source of Payment Typology" uuid="40280381-3d61-56a7-013e-6abd73f9507c" version="1"/><qdm codeSystemName="National Quality Forum" datatype="Patient Characteristic Birthdate" id="40280381-3d61-56a7-013e-6abd73f9507d" name="birth date" oid="2.16.840.1.113883.3.560.100.4" suppDataElement="false" taxonomy="LOINC" uuid="40280381-3d61-56a7-013e-6abd73f9507d" version="1"/><qdm codeSystemName="National Quality Forum" datatype="Timing Element" id="40280381-3d61-56a7-013e-6abd73f9507e" name="Measurement Period" oid="2.16.840.1.113883.3.67.1.101.1.53" suppDataElement="false" taxonomy="NQF" uuid="40280381-3d61-56a7-013e-6abd73f9507e" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73f9507f" instance="Occurrence A" name="Breast Cancer" oid="2.16.840.1.113883.3.526.3.389" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73f9507f" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95080" instance="Occurrence A" name="Office Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1001" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73f95080" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95081" name="Office Visit" oid="2.16.840.1.113883.3.464.1003.101.12.1001" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73f95081" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73f95083" name="Patient Provider Interaction" oid="2.16.840.1.113883.3.526.3.1012" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73f95083" version="1"/><qdm codeSystemName="National Quality Forum" datatype="Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6abd73f95084" name="Female" oid="2.16.840.1.113883.3.560.100.2" suppDataElement="false" taxonomy="Administrative Sex" uuid="40280381-3d61-56a7-013e-6abd73f95084" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5087" name="Breast Cancer Primary Tumor Size T0" oid="2.16.840.1.113883.3.526.3.1304" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5087" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5088" name="Breast Cancer Primary Tumor Size T1" oid="2.16.840.1.113883.3.526.3.1305" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5088" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5089" name="Breast Cancer Primary Tumor Size T1a" oid="2.16.840.1.113883.3.526.3.1164" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5089" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508a" name="Breast Cancer Primary Tumor Size T1b" oid="2.16.840.1.113883.3.526.3.1270" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508a" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508b" name="Breast Cancer Primary Tumor Size T1c" oid="2.16.840.1.113883.3.526.3.1306" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508b" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508c" name="Breast Cancer Primary Tumor Size T1mi" oid="2.16.840.1.113883.3.526.3.1197" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508c" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508d" name="Breast Cancer Regional Lymph Node Status N1" oid="2.16.840.1.113883.3.526.3.1329" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508d" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508e" name="Breast Cancer Regional Lymph Node Status pN1a" oid="2.16.840.1.113883.3.526.3.1311" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508e" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa508f" name="Breast Cancer Regional Lymph Node Status pN1b" oid="2.16.840.1.113883.3.526.3.1330" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa508f" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5090" name="Breast Cancer Regional Lymph Node Status pN1c" oid="2.16.840.1.113883.3.526.3.1331" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5090" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5091" name="Breast Cancer Regional Lymph Node Status pN1mi" oid="2.16.840.1.113883.3.526.3.1312" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5091" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5092" name="Breast Distant Metastasis Status M0" oid="2.16.840.1.113883.3.526.3.1302" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5092" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5093" name="Breast Cancer Primary Tumor Size T2" oid="2.16.840.1.113883.3.526.3.1307" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5093" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5094" name="Breast Cancer Primary Tumor Size T3" oid="2.16.840.1.113883.3.526.3.1308" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5094" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5095" name="Breast Cancer Primary Tumor Size T4" oid="2.16.840.1.113883.3.526.3.1309" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5095" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5096" name="Breast Cancer Regional Lymph Node Status N0" oid="2.16.840.1.113883.3.526.3.1310" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5096" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5097" name="Breast Cancer Regional Lymph Node Status N3" oid="2.16.840.1.113883.3.526.3.1314" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5097" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fa5098" name="Breast Cancer Regional Lymph Node Status N2" oid="2.16.840.1.113883.3.526.3.1313" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5098" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Order" id="40280381-3d61-56a7-013e-6abd73fa5099" name="Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1315" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa5099" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Active" id="40280381-3d61-56a7-013e-6abd73fa509a" instance="Occurrence A" name="Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1315" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa509a" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Intolerance" id="40280381-3d61-56a7-013e-6abd73fa509d" name="Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1315" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa509d" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73fa509e" name="Intolerance to Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1318" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa509e" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73fa509f" name="Allergy to Tamoxifen or Aromatase Inhibitor Therapy" oid="2.16.840.1.113883.3.526.3.1317" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa509f" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Active" id="40280381-3d61-56a7-013e-6abd73fa50a0" name="Gonadotropin-releasing hormone analogue medication" oid="2.16.840.1.113883.3.526.3.1316" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fa50a0" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a1" name="Bilateral Oophorectomy" oid="2.16.840.1.113883.3.526.3.471" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a1" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnosis, Active" id="40280381-3d61-56a7-013e-6abd73fb50a2" name="Metastatic Sites Common to Breast Cancer" oid="2.16.840.1.113883.3.526.3.447" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a2" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Patient Characteristic Clinical Trial Participant" id="40280381-3d61-56a7-013e-6abd73fb50a3" name="Clinical Trial Participant" oid="2.16.840.1.113883.3.526.3.1125" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a3" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a5" name="Chemotherapy" oid="2.16.840.1.113883.3.526.3.485" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a5" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fb50a6" name="Medical Reason" oid="2.16.840.1.113883.3.526.3.1007" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a6" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fb50a7" name="Patient Reason" oid="2.16.840.1.113883.3.526.3.1008" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a7" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6abd73fb50a8" name="System Reason" oid="2.16.840.1.113883.3.526.3.1009" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a8" version="1"/><qdm codeSystemName="National Committee for Quality Assurance" datatype="Encounter, Performed" id="40280381-3d61-56a7-013e-6abd73fb50a9" instance="Occurrence A" name="Face-to-Face Interaction" oid="2.16.840.1.113883.3.464.1003.101.12.1048" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50a9" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="40280381-3d61-56a7-013e-6abd73fb50aa" name="Radiation Therapy II" oid="2.16.840.1.113883.3.526.3.1339" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6abd73fb50aa" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Medication, Allergy" id="40280381-3d61-56a7-013e-6aeaa35851dc" name="Tamoxifen or Aromatase Inhibitor Therapy Allergen" oid="2.16.840.1.113883.3.526.3.1487" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6aeaa35851dc" version="1"/></elementLookUp><strata displayName="Stratification"><clause displayName="Stratum 1" type="stratum" uuid="40280381-3d61-56a7-013e-6abdda655130"><logicalOp displayName="AND" type="and"/></clause></strata></measure>
